Phosphoric Acid

Phosphoric Acid

SCHEMBL4138989

CC#N.CO.O.O=P(O)(O)O

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.40
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL2396755 1.00 CA2 (0.40) CA2LMNA
Phosphoric Acid SCHEMBL29173940 0.96 CA2 (0.38) CA2
Phosphoric Acid SCHEMBL28014825 0.96 CA2 (0.38) CA2
Phosphoric Acid SCHEMBL17555384 0.96 CA2 (0.43) CA2LMNA
Phosphoric Acid SCHEMBL6383668 0.96 CA2 (0.43) CA2LMNA
Phosphoric Acid SCHEMBL8505699 0.96 CA2 (0.43) CA2LMNA
Phosphoric Acid SCHEMBL854955 0.96
Phosphoric Acid SCHEMBL7601322 0.96 CA2 (0.43) CA2LMNA
Phosphoric Acid SCHEMBL675651 0.96
Phosphoric Acid SCHEMBL6036466 0.96 CA2 (0.43) CA2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118191132-A Analysis method for detecting impurities including nitrosamine in levosalbutamol hydrochloride 山东泰合医药科技有限公司 2024-06-14 CN claimed
CN-104592049-A Raw material medicine and preparations of pregabalin LI XINGHUI 2015-05-06 CN claimed
CN-103159636-B Aminomethyl caproic acid derivatives and uses LI XINGHUI 2015-02-25 CN claimed
CN-103159636-A Aminomethyl caproic acid derivatives and uses LI XINGHUI 2013-06-19 CN claimed
CN-102507836-A Quality detection method of menstruation regulating pill DARENTANG PHARMACEUTICAL FACTORY TIANJIN ZHONGXIN PHARMACEUTICAL GROUP CO LTD 2012-06-20 CN claimed
CN-101303333-A Method for evaluating beer aging degree with high-efficiency liquid phantom method UNIV JIANGNAN (CN) 2008-11-12 CN claimed
CN-118191132-A Analysis method for detecting impurities including nitrosamine in levosalbutamol hydrochloride 山东泰合医药科技有限公司 2024-06-14 CN disclosed
CN-115537036-B Process for purifying safflower red pigment by macroporous resin 浙江中医药大学 2024-05-10 CN disclosed
CN-115703711-A Preparation method of levalbuterol alkoxide 南京济群医药科技股份有限公司 2023-02-17 CN disclosed
CN-111175423-B Method for analyzing nedaplatin 江苏奥赛康药业有限公司 2022-07-12 CN disclosed
CN-112305088-B Analysis method of 4-demethoxydaunorubicin related substances for injection 南京正大天晴制药有限公司 2022-07-05 CN disclosed
CN-112409382-A Synthesis method of cefetamet pivoxil hydrochloride 浙江普洛得邦制药有限公司 2021-02-26 CN disclosed
CN-112409362-A Crystal of intermediate compound of lapatinib and preparation method thereof 苏州鹏旭医药科技有限公司 2021-02-26 CN disclosed
CN-1600817-A Yellow pigment of safflower preparation method and application YONGNING PHARMACEUTIC MFG PLAN (CN) 2005-03-30 CN disclosed
US-20050064028-A1 Pharmaceutical compositions containing plasma protein SICOR INC. 2005-03-24 US disclosed
US-6743826-B1 DELIVERY OF COMPOUNDS HAVING POOR WATER SOLUBILITY; BINDING AFFINITY TO PLASMA PROTEINS BY WAY OF NON-COVALENT BONDS; SERUM ALBUMIN AND GAMMA GLOBULIN; PACLITAXEL, AMPHOTERICIN B, CAMPTOTHECIN, CARBAMAZEPINE, CYCLOSPORIN A; PROPOFOL HUMAN RT (HU) 2004-06-01 US disclosed
US-6737085-B2 NATURALLY DERIVED ANTIDEPRESSANT COMPOSITION IN THE FORM OF A FOOD, DIETARY SUPPLEMENT, MEDICINE OR THE LIKE THAT CONTAINS NEITHER HYPERICIN NOR HYPERFORIN AND IS SAFER EVEN DURING EXTENDED ADMINISTRATION, FOR THERAPY OF DEPRESSION TOKIWA PHYTOCHEMICAL CO., LTD. (JP) 2004-05-18 US disclosed
EP-0981375-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING PLASMA PROTEIN HUMAN RT (HU) 2003-01-08 EP disclosed
US-20020090403-A1 Antidepressant TOKIWA PHYTOCHEMICAL CO., LTD. (JP) 2002-07-11 US disclosed
US-6113907-A MEASUREMENT OF SAMPLE, BINDING AND DETERMINATION OF HYPERICIN CONCENTRATION FOR MUSCARINIC M1 RECEPTORS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2000-09-05 US disclosed